Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$472.00 USD
+0.56 (0.12%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $471.33 -0.67 (-0.14%) 8:36 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Vertex Pharmaceuticals (VRTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$506.11 | $600.00 | $325.00 | 7.23% |
Price Target
Based on short-term price targets offered by 27 analysts, the average price target for Vertex Pharmaceuticals comes to $506.11. The forecasts range from a low of $325.00 to a high of $600.00. The average price target represents an increase of 7.23% from the last closing price of $472.00.
Analyst Price Targets (27)
Broker Rating
Vertex Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.87 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 30 brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on 30 recommendations.
Of the 30 recommendations deriving the current ABR, 19 are Strong Buy, representing 63.33% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 20 | 19 | 19 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 8 | 8 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 1.87 | 1.87 | 1.80 | 1.83 | 1.87 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | Not Identified | Not Identified | Strong Buy | Hold |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/2/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
8/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
7/31/2024 | Canaccord Genuity | Whitney Ijem | Strong Sell | Strong Sell |
7/26/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
7/23/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
7/19/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
7/16/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
6/27/2024 | Atlantic Equities | Steven K Chesney | Not Available | Strong Buy |
6/24/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
6/24/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
6/17/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
5/31/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/7/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
5/7/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Hold | Hold |
5/7/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Hold | Hold |
4/17/2024 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
4/11/2024 | Evercore Partners | Liisa A Bayko | Hold | Strong Buy |
1/31/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Strong Sell |
1/30/2024 | Maxim Group | Naz Rahman | Strong Buy | Hold |
12/1/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.87 |
ABR (Last week) | 1.87 |
# of Recs in ABR | 30 |
Average Target Price | $506.11 |
LT Growth Rate | 12.50% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 74 of 253 |
Current Quarter EPS Est: | 4.11 |